Treat-to-target (T2T) for gout has been established recently to improve its management, which has been reported to be sub-optimal with significant gaps between the goals of treatment and day-to-day clinical practice. T2T recommended a goal of serum urate (SUA) target of <360 μmoI/L in all patients with gout and <300 μmoI/L in patients with tophaceous or severe gout. T2T strategy was applied in the management of gout patients in two Rheumatology clinics from 1 January 2016 onwards. We performed a clinical audit to assess T2T of SUA in gout patients and to identify causes for failure to achieve target SUA among them. There were a total of 304 patients for our analysis. They were of multi-ethnic origin with male predominance (88.8%). They had a mean age of 57.7+13.7 years and mean disease duration of 10.1+8.7 years. The most common comorbidities were hypertension (76.2%), dyslipidemia (52.5%) and diabetes mellitus (DM) (27.4%). Our patients' body mass indexes showed that 47.7% were obese while 34.2% were overweight. Up to 62.4% of our patients had tophi and 42.6% had joint deformities. Only 34.9% of patients achieved target SUA. Nonadherence (52.3%) was the main reason identified for failure to achieve target SUA. The independent predictors for failure to achieve target SUA were nonadherence (HR=7.84, p=0.000) and presence of tophi (HR=1.95, p=0.001).
n INTRODUCTION G out is the most common inflammatory arthritis worldwide. The prevalence and incidence of gout is increasing (1) due to global aging, dietary and lifestyle changes. There is a strong association between gout and other metabolic disorders such as hypertension, dyslipidemia and DM (2) (3) (4) . Gout is also an independent risk factor for cardiovascular morbidity and mortality. Treat-to-target (T2T) guidelines for gout have been published in recent years to guide clinicians in managing gout patients. These treatment guidelines (5-7) support a treat-to-target strategy in gout with a goal of SUA target of <360 μmoI/L in all patients with gout and <300 μmoI/L in those with tophaceous or severe gout. Evidence suggest failure to achieve treatment goals in gout is associated with worsening outcomes such as recurrent flares, tophi and joint deformities. Gout is often misdiagnosed and inadequately treated with significant gaps between the goals of treatment and actual clinical practice (8) (9) (10) (11) . We performed a clinical audit to assess T2T of SUA in gout patients and to investigate the causes of failure to achieve target SUA among our patients.
n MATERIALS AND METHODS T2T strategy was applied in of all our patients with gout who were managed in two rheumatology clinics in Sarawak from 1 Jan 2016 onwards. A retrospective case notes review was carried out from 1 st June 2017 through 31 st December 2017 to assess T2T of SUA. All patients who were diagnosed with gout according to 1977 American Rheumatism Association preliminary criteria for the classification of the acute arthritis of pri-Treat-to-target (T2T) of serum urate (SUA) in gout: a clinical audit in real-world gout patients Treat-to-target (T2T) of serum urate (SUA) in gout: a clinical audit in real-world gout patients ORIGINAL PAPER mary gout (12) were included in the study. Demographics of patients, date of gout onset, duration of disease and comorbidities (including hypertension, DM, dyslipidemia and stroke) were collected from patient case notes. We also evaluated clinical presentation of gout, treatment regimes (for both acute and chronic gout) and laboratory investigations (including SUA at first visit and at last follow-up, glucose level and lipids profile). Renal function was measured using serum creatinine which was available from the patient records and classified according to the KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (13) . Nonadherence was defined as documentation of any non-compliance with medical therapy in the medical records. The major outcome was achievement of SUA of <360 μmoI/L in all patients with gout and <300 μmoI/L in those with tophaceous or severe gout. The major outcome was determined based on the latest serum urate level of the patients. Data was collected till patients' last follow up during the study period. Analysis was performed using SPSS version 10.0 (SPSS, Chicago IL, USA). Results are presented as frequencies and percentages for categorical variables and as means and standard deviations (SD) for continuous variables. The risk factors associated with failure to achieve SUA were assessed using multivariate Cox regression analysis.
n RESULTS

Patients' characteristics
There were a total of 304 patients available for our analysis. Our patients were of multi-ethnic origins with a male predominance (271 males versus 33 females). They had a mean age of 57.7+13.7 years and a mean disease duration of 10.1+8.7 years as illustrated in Table I . The most common comorbidities in our patients were hypertension (76.2%), dyslipidemia (52.5%) and DM (27.4%). Ischemic heart disease was found in 10.6% of patients while 7.3% had a stroke. In this current study, 36% of pa-tients had more than two comorbidities. Grade 2 Chronic Kidney Disease (CKD) was present in 41.9% of patients while Grade 3 CKD was present in 32.7%. Grade 4 CKD was present in 8.9% of patients and 3.6% of patients had End Stage Renal Failure. Body mass indexes were available in 73.6% of patients in which 48% were obese while 35% were overweight. Most of our patients were smokers (73.4%). Alcohol consumption was reported among 20.1% of patients. Positive family history of gout was found in 33.9% of patients.
Pattern of gout
Up to 62.4% of our patients had tophi and 42.6% had joint deformities. Only 9.9% 
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of patients had history of uric acid stones and only 9.2% had history of uric acid nephropathy. Patients with tophi were found to have a longer disease duration than those without tophi (11.6+8.8 years vs 7.6+8.1 years, p=0.000). They were more likely to consume alcohol compared to those without tophi (p=0.008). There were no differences in prevalence of hypertension, dyslipidemia and chronic kidney disease between these two groups of patients. (Tables III and IV) . Age, gender, ethnicity, presence of comorbidities and presence of CKD were not associated with failure to achieve target SUA. Alcohol consumption was associated with nonadherence to treatment (HR=2.36, p=0.000). Age, number and types of comorbidities as well as presence of tophi were not associated with nonadherence.
n DISCUSSION
Our study showed that only 34.9% of gout patients achieved the target SUA recommended by T2T; this figure is significantly lower than that reported in studies in which up to 80% of patients were able to achieve the treatment goal (14) (15) (16) . This is most probably due to the fact that our patients were complicated gout patients with tophi and erosions. The majority of our patients had chronic tophaceous gout with a significant burden of hypertension, dyslipidemia, DM and obesity. In this, they were similar to the reported rates of metabolic disorders from other studies worldwide (2) (3) (4) . Our patients also had a high incidence of chronic kidney disease which limited the optimal use of ULT in achieving target serum urate levels.
Patients who achieved target SUA had a longer disease duration and were treated longer than those who failed to achieve target SUA. They were also on higher mean daily allopurinol doses. This finding shows that achieving target SUA is feasible with a longer treatment period and a higher allopurinol dose. Barriers to achieving target SUA include patient factors and physician factors. Poor understanding of the disease, stigmatization of gout and nonadherence to treatment were the main patient factors identified in failure to achieve target SUA. Physician factors included knowledge gaps, including specialized knowledge of the disease, and clinical inertia in implementing guidelines. Nonadherence was the main reason for failure to achieve target SUA in this current 
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study. Adherence to ULT in gout has been reported as ranging from 18%-44%; one of the lowest among patients with chronic diseases (17) (18) (19) (20) (21) . Nonadherence has been reported as a common cause for ULT failure (20, 22) . Rashid et al. showed that adherent patients were 2.5-fold more likely than nonadherent patients to achieve an SUA <6.0 mg/dL in their study (23) . Younger age, fewer comorbidities or gout complications, race, and prescriber type predicted poor adherence to ULT (24, 25) . One recent meta analysis showed that older age, more comorbidities, and the presence of DM or hypertension were associated with medication adherence among patients with gout (21) . Concomitant diuretic use, prescriber specialty, and allopurinol dosing practices had been identified as potentially modifiable factors associated with treatment adherence and achieving treatment target (23) . Use of nonsteroidal anti-inflammatory drugs (NSAIDs) and systemic glucocorticoids reduced resumption of allopurinol therapy after a period of non-adherence (22) . We found that alcohol consumption was associated with nonadherence among our patients. Alcohol use has been reported to be associated with nonadherence in other medical conditions (26, 27) . In contrast, age of patients, number and type of comorbidities, tophi and renal failure were not associated with nonadherence in this current study. Nonadherence to ULT remained the major hurdle in the management of gout patients. Patient education that focuses on pharmacologic therapy and lifestyle modifications with medication titration has been found to improve adherence, reduce the number of attacks, and improve the number of patients who achieved T2T of SUA (14) (15) (16) 28) . Optimization of control of SUA is achievable, even in the setting of renal impairment, by redesigning and implementing processes involving changes in physicians' prescribing habits, enhanced nursing interventions, and patient empowerment and education (14) .
There are a few limitations to this study. Firstly, there was selection bias as only gout patients undergoing follow-up at rheumatology departments were included in this study. Our cohort had severe or complex gout. Secondly, we did not collect any patient reported outcomes. Nevertheless, our study reported experience of real-life data of gout patients treated in daily clinical practice.
In summary, we found that the majority of our gout patients failed to achieve target SUA. Nonadherence was the main cause of failure to achieve SUA. Nonadherence and presence of tophi were independent prognostic predictors of failure to achieve SUA. Alcohol consumption was associated with nonadherence to treatment. 
